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Use of Selective Serotonin Reuptake Inhibitors During Pregnancy and
Risk of Congenital Cardiac Malformations
Abstract
Background
Untreated maternal depression has been shown to have adverse effects in many children, yet how the mother
should be treated is not clear and can vary with the situation. The use of selective serotonin reuptake
inhibitors (SSRIs) during the first trimester of pregnancy carries with it potential risk of congenital cardiac
malformation, but individual studies and systematic analyses vary in their results.
Methods
A literature search was performed using MEDLINE-Ovid, Web of Science, Cochrane, and Google Scholar
using the terms “SSRI,” “pregnancy,” and “birth defect.” The term “birth defect” was used rather than a term
more specific to the heart (e.g. “cardiac malformation”) in order to keep the search sufficiently broad. The
search was further restricted to studies published in the English language between 2010 and 2015. The
MEDLINE search also included the terms “serotonin uptake inhibitors,” “pregnancy outcomes,” and
“congenital abnormalities.” In addition to database searches, bibliographies from select journal articles were
reviewed for potential sources of relevant articles. Articles were assessed using GRADE criteria
(www.gradeworkinggroup.org).
Results
Two studies were found which met the inclusion and exclusion criteria, one from the US and the other from
the UK, both of which were cohort studies. There was no significant increase of risk regarding exposure to
SSRIs as a class of medication in either study. The RR for general SSRI exposure in the US study was 1.02
(95% CI, 0.90–1.15). The aOR for overall SSRI exposure in the UK study ranged from 1.03 to 1.14. There was
a significant increase of risk with paroxetine exposure in the UK study, evidenced by an aOR of 1.78 (95% CI,
1.09–2.88).
Conclusion
The studies demonstrated low risk of congenital cardiac malformation with exposure to SSRIs as a general
class. However, paroxetine and sertraline exposure showed elevated risk that was sometimes considered
significant. The decision to treat maternal depression with SSRIs should involve recent and reliable literature,
as well as involve the patient.
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Abstract   
Background Untreated maternal depression has been shown to have adverse effects in many children, yet how the mother should be treated is not clear and can vary with the situation. The use of selective serotonin reuptake inhibitors (SSRIs) during the first trimester of pregnancy carries with it potential risk of congenital cardiac malformation, but individual studies and systematic analyses vary in their results. 
Methods A literature search was performed using MEDLINE-Ovid, Web of Science, Cochrane, and Google Scholar using the terms “SSRI,” “pregnancy,” and “birth defect.” The term “birth defect” was used rather than a term more specific to the heart (e.g. “cardiac malformation”) in order to keep the search sufficiently broad. The search was further restricted to studies published in the English language between 2010 and 2015. The MEDLINE search also included the terms “serotonin uptake inhibitors,” “pregnancy outcomes,” and “congenital abnormalities.” In addition to database searches, bibliographies from select journal articles were reviewed for potential sources of relevant articles. Articles were assessed using GRADE criteria (www.gradeworkinggroup.org). 
Results  Two studies were found which met the inclusion and exclusion criteria, one from the US and the other from the UK, both of which were cohort studies. There was no significant increase of risk regarding exposure to SSRIs as a class of medication in either study. The RR for general SSRI exposure in the US study was 1.02 (95% CI, 0.90–1.15). The aOR for overall SSRI exposure in the UK study ranged from 1.03 to 1.14. There was a significant increase of risk with paroxetine exposure in the UK study, evidenced by an aOR of 1.78 (95% CI, 1.09–2.88). 
Conclusion The studies demonstrated low risk of congenital cardiac malformation with exposure to SSRIs as a general class. However, paroxetine and sertraline exposure showed elevated risk that was sometimes considered significant. The decision to treat maternal depression with SSRIs should involve recent and reliable literature, as well as involve the patient. 
Keywords Depression, maternal depression, pregnancy, SSRI, selective serotonin reuptake inhibitor, antidepressant, birth defect, congenital defect, congenital malformation, heart defect, cardiac defect.   
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Use of Selective Serotonin Reuptake Inhibitors During Pregnancy 
and Risk of Congenital Cardiac Malformations 
 
BACKGROUND  The prevalence of maternal depression during pregnancy is noteworthy. The literature does not agree on the prevalence, with one study stating it ranges anywhere from 10% to 30%,1 while another places it at 18.4%.2 Regardless of the number of women with depression during pregnancy, treating the depression—by some method—has been shown to be very consequential because untreated depression during pregnancy can adversely affect the mother and fetus. Depression during pregnancy is associated with preeclampsia, premature birth, low weight birth, and elective abortion.3 Postpartum depression has been shown to contribute to developmental problems such as temperament, attachment insecurity, missed pediatric appointments, increased utilization of emergency services, and impaired language development.2,3  There are multiple treatment modalities for maternal depression, including pharmacological, non-pharmacological, or a combination of the two. The majority of pharmacological treatment (75%) is with a class of antidepressants called selective serotonin reuptake inhibitors (SSRIs).4 It is incumbent, therefore, to understand the risks to the developing child that are posed with the use of SSRIs during pregnancy.  Serotonin is a naturally occurring neurotransmitter secreted within the human body. Most commonly it is thought to function in the central nervous system for the regulation of mood. Aside from this well-known area of involvement, serotonin is also critical for the development of the heart during embryogenesis.5 Selective serotonin reuptake inhibitors (SSRIs) are a type of antidepressant which alter the levels of serotonin 
5 
in the circulation and are believed to have a potential impact on cardiac development during the first trimester of pregnancy, when organogenesis is occurring (3–8 weeks post conception).  There are manifold studies on SSRIs and how they affect overall perinatal and antenatal development of the child, but no individual study, meta-analysis, or systematic review of studies has been definitive. One review demonstrated a more than twofold difference in the number of studies that show no malformation risks (negative studies) and studies that show malformation risk (positive studies), the former being greater in prevalence.6  Of the various problems that are believed to occur during the first trimester, increased risk of cardiac malformation is frequently higher in many studies.7-9 In many cases the increased risk is considered not significant, but the fact that it is a regular occurrence in some studies has brought increased scrutiny to that particular issue. Until 2005, all SSRIs were labeled by the FDA as pregnancy category C drugs. However, in December of that year paroxetine was reclassified as pregnancy category D after early testing by the manufacturer GSK (GlaxoSmithKline) showed a significant increase in heart defects—up to twice the rate compared to women on another antidepressant or no antidepressant.10 It is important to note that these results were from early testing, were not peer-reviewed, and that such results have not occurred since.  What follows is a review of two of the many articles that comprise the significant collection of study on the subject. This review reflects the outcomes and conclusions of the majority of that body of literature.   
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METHODS  An exhaustive literature search was performed using MEDLINE-Ovid, Web of Science, Cochrane, and Google Scholar using the terms “SSRI,” “pregnancy,” and “birth defect.” The term “birth defect” was used rather than a term more specific to the heart (e.g. “cardiac malformation”) in order to keep the search sufficiently broad. The search was further restricted to studies published in the English language between 2010 and 2015. Using advanced search features in Ovid, the MEDLINE search also included the search terms “serotonin uptake inhibitors,” “pregnancy outcomes,” and “congenital abnormalities.” In addition to database searches, bibliographies from select journal articles were reviewed for potential sources of relevant articles. The selected studies were assessed using criteria GRADE criteria, a method designed to evaluate quality of evidence and strength of recommendations (www.gradeworkinggroup.org). 
RESULTS  The searches within MEDLINE-Ovid, Web of Science, and Cochrane returned 122 articles. Each of these articles was examined for relevance. Google Scholar returned 483 articles but the relevancy of the articles was low, thus only 30 articles from Google Scholar were reviewed closely. Screening for duplicates and selecting the most relevant articles yielded two cohort studies.11,12 (See Table 1.)  
Huybrechts et al 
 Study Description—This observational study,11 published in 2014 in the New England Journal of Medicine, examined a cohort of 949 504 pregnant women in the United States enrolled in Medicaid during the years 2000 through 2007, and within a minimum time frame of 3 months prior to their last menstrual cycle through 1 month after delivery. 
7 
The data were drawn from the Medicaid Analytic eXtract for 46 states and Washington D.C., and included females ages 12 to 55 with completed, liveborn pregnancies. Criteria excluded subjects who had restricted benefits, supplementary insurance, or private insurance. Also excluded were subjects who had been receiving treatment with known teratogenic agents during the first trimester, as well as those whose infants were diagnosed with chromosomal abnormalities.11  Maternal use of antidepressants was established by examining pharmacy dispensing records. The study authors defined 8 exposure categories (see Table 2): any SSRI, paroxetine, sertraline, fluoxetine, tricyclic antidepressants (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), bupropion, and other antidepressants. Females with no known exposure to antidepressants during their first trimester comprised the reference group. A diagnosis of depression was not required.11  The presence of congenital cardiac malformations was determined by reviewing ICD-9 codes in maternal and infant medical records during the first 90 days following delivery. Using prior studies as a guideline, the outcomes were placed into 4 categories (see Table 3): any cardiac malformation, right ventricular outflow tract obstruction, ventricular septal defect, and other cardiac malformation. In order for an anomaly to be considered present, 1 of 2 criteria had to be met: a single instance of a diagnostic code accompanied by a code for a cardiac surgery or procedure, or a diagnostic code that was associated with more than one date. Malformations associated with prematurity were excluded (patent ductus arteriosus, pulmonary valve stenosis, and pulmonary artery anomalies).11  In an attempt to mitigate the effects of confounders, risk factors and proxies that are both known and suspected were considered: multiple gestation, use of teratogenic 
8 
substances, use of other psychotropic medications (those not included in Table 1), and chronic maternal illness (e.g. hypertension, diabetes, renal disease, and epilepsy). Coexisting conditions were estimated by considering the number of distinct prescription drugs used by the mothers. Indications for antidepressant use other than for depression—such as sleep disorders, chronic fatigue syndrome, premenstrual dysphoric disorder, pain-related diagnoses, and other mental health disorders—were also accounted for. In addition to the many covariates considered above, sociodemographic information was evaluated: the mother’s age, race, state of residence, year of delivery, and parity.11  Study Results—The outcomes underwent three levels of adjustment. In the first level of adjustment the results were simply left unadjusted. The second level, in an attempt to control for underlying illness or its related factors, was restricted to women with a documented diagnosis of depression. The third level sought to further control for depression severity proxies by restricting the results to females with depression and implementing the use of propensity-score stratification.11  In confirming the analyses, the authors used a “high-dimensional propensity-score algorithm, which evaluates thousands of diagnoses, procedures, and pharmacy-claim codes to identify and prioritize covariates that serve as proxies for unmeasured confounders.”11  Because the subjects in the study represented a broader population than previous studies, effect modification was tested according to age and race. Dose–response was also analyzed for low, medium, and high doses of antidepressants.11  Within the 949 504 eligible pregnancies that were identified, 64 389 used an antidepressant during the first trimester. Of those, 46 144 were exposed to an SSRI. The most frequently used SSRIs were sertraline (14 040 women), paroxetine (11 126), and 
9 
fluoxetine (11 048). Women who filled a prescription for an antidepressant were more likely than those with no antidepressant exposure to be white, have a chronic illness (primarily diabetes or hypertension), use other psychotropic medications, and suspected of using teratogenic medications. (Unlike the subjects with known exposure to teratogenic medications who were excluded from the study at its outset, those who were merely suspected of exposure remained in the study.)11  Overall, the unadjusted rate of cardiac malformations in infants was greater in those with antidepressant exposure (90.1 malformations per 10 000) than those who were not exposed (72.3 per 10 000). Each of the specific types of malformations considered (Table 3) demonstrated a higher unadjusted risk.11  In the first adjustment level (no adjustment) the RR of any cardiac malformation with SSRI exposure was 1.25 (95% CI, 1.13–1.38). The second adjustment level (subjects with diagnosed depression) yielded a relative risk of 1.12 (95% CI, 1.01–1.25). The third level of adjustment (depression and propensity-score stratification) showed a relative risk of 1.02 (95% CI, 0.90–1.15).11  Modification of effect was not seen according to age or race, nor was a dose–response relationship observed. Overall, SSRI exposure demonstrated a similar risk of cardiac malformation among patients of antidepressant monotherapy and polytherapy.11  Significant to note in contrast to previous studies, is the absence of association between paroxetine and right ventricular outflow tract obstruction (RR 1.07; 95% CI, 0.59–1.93) or sertraline and ventricular septal defect (RR 1.04; 95% CI, 0.76–1.41).11   
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Ban et al 
 Study Description—This cohort study12 was published in BJOG (BJOG: An International Journal of Obstetrics & Gynaecology; formerly British Journal of Obstetrics and Gynaecology) in 2014. The stated objective was to estimate the risks of major congenital anomaly among 3 groups of children: those whose mothers were diagnosed with depression and treated with antidepressants during the first trimester, those whose mothers were diagnosed with depression but not treated, and those whose mothers did not have a diagnosis of depression. They examined UK maternal–child primary care records from 1990 through 2009 for all single births to women aged 15–45 years, resulting in a study encompassing 349 127 liveborn children. They excluded those children whose mothers who were diagnosed with bipolar disorder, schizophrenia, and other significant psychotic disorders, as well as those who had prescriptions for antipsychotic or antimanic medications before childbirth.12  Major congenital anomalies (MCAs) were identified in the children’s records using Read codes and were classified into 1 of 14 system-specific categories (heart, limb, digestive, respiratory, etc.) that are based on ICD-10. Children with genetic anomalies or teratogenic-associated anomalies were excluded from the study. In addition to the 14 categories, specific types of cardiac malformations were assessed with the goal of comparing results among other studies. Those cardiac anomaly subgroups were: septal defects, right ventricular outflow tract defects, left ventricular outflow tract defects, and other (Table 4).12  For purposes of statistical analysis, the outcome group wherein the mother was diagnosed with depression and treated with antidepressants during the first trimester was 
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divided into three distinct groups: those treated with SSRIs, those treated with TCAs, and those treated with both SSRIs and TCAs. Absolute risks were calculated to determine the disease burden of the MCAs for the entire study population as well as for the five defined exposure groups. SSRIs were the most prescribed class of antidepressant, leading to the ability to estimate risk for individual drugs within that class (fluoxetine, citalopram, paroxetine, sertraline, and escitalopram). Women who were exposed to more than a single SSRI were excluded from the analysis of the individual SSRIs, but were included in the more general analyses. Odds ratios with 95% confidence intervals were calculated for overall MCA results, as well as for each of the 14 system-specific categories—all for each class of antidepressant and specific SSRIs.12  In order for the study results to be comparable with other literature, the baseline group for all comparisons within the study was children whose mothers did not have a diagnosis of depression. To determine if pharmacologically-treated depression (a.k.a. medicated depression) was associated with a greater risk of MCAs than unmedicated depression, an analysis was performed using mothers with unmedicated depression as the baseline group. Multivariable analyses were performed to account for various maternal characteristics: age, smoking history, BMI, and socioeconomic deprivation. They also adjusted for the congenital impact certain chronic illnesses can have (diabetes, hypertension, epilepsy, and asthma).12  Study Results—Within the entire study population of 349 127 single live births, 2.7% had some type of MCA (95% CI, 2.6%–2.8%). Mothers of those with MCA had similar sociodemographic profiles as those without MCA. However, sociodemographic differences 
12 
were evident when comparing mothers with depression and those without, the former having higher levels of socioeconomic deprivation, tobacco use, obesity, and asthma.12  Overall results showed there is an increased absolute risk of MCAs among children of mothers with unmedicated perinatal depression than those with without depression, though the relative risk is not significant (1.07; 95% CI, 0.96–1.18). Similarly, antidepressant exposure did not show an increased risk of MCA overall. For cardiac malformations related to all SSRI use, absolute risks were higher in children whose mothers had either unmedicated depression or medicated depression than those without depression. However, the adjusted odds ratios show no statistically significant increase (aOR ranges: 1.03–1.14).12  When further broken down into specific drugs within the SSRI class, fluoxetine exposure had a lower absolute risk (66/10 000) than those with no maternal depression (75/10 000) or unmedicated depression (83/10 000). The other SSRIs had a higher absolute risk: paroxetine (142/10 000), sertraline (119/10 000), escitalopram (90/10 000), and citalopram (87/10 000). The high absolute risk of paroxetine (142/10 000) represents a 78% increase in cardiac malformations (aOR 1.78; 95% CI, 1.09–2.88). An increase in congenital cardiac defects with sertraline exposure was also present (aOR 1.52; 95% CI, 0.78–2.96).12  When the baseline group was redefined as those with unmedicated maternal depression, most of the point estimates of the adjusted odds ratios decreased slightly for SSRIs, individual SSRIs, and TCAs. No statistically significant associations were found, but paroxetine and sertraline exposure had elevated risk when compared to other SSRIs, just as they did when the baseline group was women without a diagnosis of depression. The 
13 
adjusted odds ratios for paroxetine and sertraline were 1.67 (95% CI, 1.00–2.80; P=0.051) and 1.39 (95% CI, 0.70–2.74, P=0.345), respectively.12   Ban et al12 conclude that “MCA and system-specific anomaly risks were similar in children of mothers with and without antidepressants (SSRIs or TCAs) in early pregnancy.”12 The only evidence of increased risk of congenital cardiac malformations associated with SSRI exposure were with paroxetine and (though not statistically significant) sertraline. In addition, most of the heart anomalies associated with paroxetine exposure were relatively mild conditions and were not related to a specific type of heart anomaly.12 
DISCUSSION  The importance of treating depression in pregnant women cannot be overstated, but difficulties quickly arise when determining the treatment plan. Will the patient benefit sufficiently from non-pharmacological treatments only? Considering that untreated depression can adversely affect pregnancy outcomes, is the risk of withholding pharmacotherapy greater than prescribing antidepressants? Which antidepressant is the safest? Why is there so much variation in the literature? These and other questions are not easily answered and should be addressed using as much reliable and up-to-date research as possible, in concert with patient preferences.  Understandably, the issues surrounding pregnancy are charged with emotion. Patients who might otherwise be ambivalent about their own health and healthcare often become very protective and concerned about their unborn children. The proliferation of discrepant information available to patients regarding SSRI safety can be very confusing. Earlier this year when reporting about a just-published BMJ article on SSRI risk,13 the 
14 
headlines from two trusted sources were quite different. A Reuters article started with “Study links Prozac, Paxil use with birth defects”14 while The Wall Street Journal’s headline read “Birth-defect risk from antidepressants is seen as small.”15 Pfizer’s recent successes in court defending themselves against lawsuits alleging a connection between Zoloft (sertraline) and birth defects16 are also bound to add to the doubt and frustration experienced by patients. It is important that the clinician be able to explain the issues and reassure their patients as they come to a decision on treatment options. It is also important for the clinician to understand that women who are depressed may have a higher perception of teratogenic risk of a given medication—often unrealistically so—and take it into account when counseling them about the potential risks of SSRIs.17  Both studies11,12 agree that there is no significant risk for congenital cardiac malformation in children whose mothers were exposed to SSRIs during their first trimester of pregnancy. The relative risk (Huybrechts et al11) and adjusted odds ratios (Ban et al12) were not significant. They also agree that when looking at individual drugs within the SSRI class both paroxetine and sertraline have increased risk, though the outcomes differ between studies. (See Table 6.) Elevated risk with exposure to paroxetine and sertraline are consistent with other studies, though not all of them.3 Paroxetine was reclassified in 2005 to a pregnancy class D drug4 and sertraline exposure has been associated with an increase in septal defects and craniosynostosis.18  Both studies11,12 were crafted with consideration of similar, related literature in order to contribute to and be used by those in the medical research community who are attempting to determine the safety of using SSRIs during pregnancy. The authors utilized comprehensive approaches to correct and adjust for confounders, and performed a variety 
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of extensive analyses, all of which contribute to the overall validity of the studies. They also attempted to draw from a representative pool. Huybrechts et al11 used data from US Medicaid records. Medicaid beneficiaries have a poorer health profile when compared with those who are privately insured or have no insurance19 and Medicaid provides coverage for medical expenses for over 40% of births in the United States.20 This difference could lead to study results that are not representative of the general US population. However, Huybrechts et al11 state that they did not find any impact due to sociodemographic characteristics during their analysis and conclude that their study should be generalizable to other populations. Ban et al12 used primary care records in the UK, ensuring a strong link to the population in general.  This paper only addressed congenital cardiac malformations, but other areas of risk have been found and studied. One phenomenon, postnatal adaptation syndrome (PNAS), has been consistently noted in several studies3,7,8 occurring in 5%–30% of neonates who were exposed to SSRIs.7 PNAS, which is also referred to as poor neonatal adaptation syndrome and neonatal behavior syndrome, presents with a variety of symptoms, including irritability, tachypnea, hypothermia, hypoglycemia, and (occasionally) respiratory distress.3,7 Though PNAS consistently appears to be a somewhat frequent occurrence, this condition is usually not serious and resolves within days or weeks of delivery.  To better understand the results of the GRADE evaluation, it is helpful to note that by definition cohort studies begin with a “low” rating. There were no significant limitations or flaws in either study11,12 that led to downgrading them. And while it is possible to upgrade observational studies, it very difficult to do when dealing with the question of harm. These studies then, retained their “low” rating. 
16 
 In an article examining the risks and benefits of antidepressant use during pregnancy6, the authors note that study outcomes can be adversely affected by significant limitations inherent in study design. They state that retrospective studies (those which use registries like the Medicaid Analytic eXtract) are not designed to study drug safety, a fact that should be taken into account when interpreting outcomes6. Another potential problem with retrospective studies is that although prescription records may imply that a woman is taking her medication as prescribed, that is not necessarily the case. In general, drug adherence for mental illness has been shown to be less than 50%.6  Ascertainment bias can also occur in studies which examine the use of SSRIs during pregnancy and falsely imply a relationship between usage of the drug and congenital malformations. This can occur because women with depression have higher likelihood of undergoing ultrasound scans and echocardiograms than healthy women, increasing the chances of discovering a problem. Additionally, women with depression are more likely to utilize emergency services with their infants, again increasing the chances that a defect is found that, although present, might not be found in the child of someone who doesn’t go to the emergency department as often.6  
CONCLUSION  While the two studies11,12 suggest a low relative risk of congenital cardiac malformation in children whose mothers used SSRIs during pregnancy, it seems prudent based on the evidence to avoid the use of paroxetine and sertraline if possible. Other SSRIs have been shown herein to have risks that are considered not significant and should probably be given preference. Because there are SSRIs that present minimal risk to the 
17 
fetus, pharmacological treatment for maternal depression does not need to be eschewed when determining a treatment plan.  It is a truism in research that more research is beneficial and preferred to less. And in this case, one place to start may be to determine why some studies demonstrate risk with paroxetine and sertraline exposure while others do not. Attempting to compare and harmonize the many studies should lead to an increased safety profile for SSRI use during pregnancy.    
18 
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Tables 
 
Table 1 – Characteristics of Reviewed Studies 
Study 
 
Design Downgrade Criteria Quality 
Limitations Indirectness Inconsistency Imprecision Publication Bias 
Huybrechts et al11 cohort not serious not serious not serious not serious not serious low 
Ban et al12 cohort not serious not serious not serious not serious not serious low 
 
Table 2 – Exposure Categories (Huybrechts et al)11 
any SSRI 
paroxetine 
sertraline 
fluoxetine 
tricyclic antidepressants 
serotonin–norepinephrine reuptake inhibitors 
bupropion 
other antidepressants 
 
Table 3 – Categories of Congenital Cardiac Malformations (Huybrechts et al)11 
any cardiac malformation 
right ventricular outflow tract obstruction 
ventricular septal defect 
other cardiac malformation 
 
Table 4 – Categories of Congenital Cardiac Malformations (Ban et al)12 
septal defects [including atrial septal defect, ventricular septal defect, and atrioventricular septal defect] 
right ventricular outflow tract defects 
left ventricular outflow tract defects 
other cardiac malformation [including transposition of great vessels, total anomalous pulmonary venous connection, 
coarctation of the aorta, Ebstein’s anomaly, tricuspid atresia and stenosis, patent ductus arteriosus, single ventricle, tetralogy 
of Fallot, and truncus arteriosus] 
 
Table 5 – SSRIs During the First Trimester of Pregnancy (Ban et al)12 
MCAs Fluoxetine 
n=3189 
Citalopram 
n=1946 
Paroxetine 
n=1200 
Sertraline 
n=757 
Escitalopram 
n=333 
n/ 
10 000 
aOR 
(95% CI) 
n/ 
10 000 
aOR 
(95% CI) 
n/ 
10 000 
aOR 
(95% CI) 
n/ 
10 000 
aOR 
(95% CI) 
n/ 
10 000 
aOR 
(95% CI) 
All 
combined 
241 0.91 
(0.73–1.15) 
267 1.06 
(0.80–1.40) 
300 1.08 
(0.77–1.50) 
330 1.27 
(0.85–1.89) 
210 0.85 
(0.40–1.81) 
Heart 66 0.84 
(0.55–1.30) 
87 1.13 
(0.70–1.82) 
142 1.78 
(1.09–2.88) 
119 1.52 
(0.78-2.96) 
90 1.15 
(0.36–3.65) 
21 
Table 6 – Summary of Findings 
Study Risk of Cardiac Malformation 
All SSRIs Paroxetine Sertraline 
Huybrechts et al11 RR 1.02 (95% CI, 0.90–1.15)a RR 1.07 (95% CI, 0.59–1.93)b RR 1.04 (95% CI, 0.76–1.41)c 
Ban et al12 aOR ranges: 1.03–1.14d aOR 1.78 (95% CI, 1.09–2.88)e aOR 1.52 (95% CI, 0.78–2.96)f 
a - Third level of adjustment (depression of diagnosis and propensity-score stratification); considered not significant 
b - right ventricular outflow tract obstruction; considered not significant 
c - ventricular septal defect; considered not significant 
d - includes 4 categories: unmedicated depression, SSRIs alone, TCAs alone, SSRIs and TCAs; considered not significant 
e - various defects; only outcome considered significant 
f - considered not significant 
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